Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Research

LncRNA-Gm9795 promotes inflammation in non-alcoholic steatohepatitis via NF-\(\kappa {}\)B/JNK pathway by endoplasmic reticulum stress

Authors: Liangying Ye, Dan Zhao, Yangzhi Xu, Jiaen Lin, Jiahui Xu, Kunyuan Wang, Zhanhui Ye, Yufeng Luo, Shiming Liu, Hui Yang

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Background

Non-alcoholic steatohepatitis (NASH) is a key stage in leading development of non-alcoholic simple fatty liver (NAFL) into cirrhosis and even liver cancer. This study aimed at exploring the lncRNAs expression profile in NASH and the biological function of a novel LncRNA-gm9795.

Methods

Microarray analysis was performed to compare the expression profiles of lncRNAs in the liver of NASH, NAFLD and normal mice (5 mice for each group). Methionine-choline-deficient Medium (MCD) with Lipopolysaccharide (LPS) or palmitic acid (PA)were used to built NASH cell models. The role and mechanism of LncRNA-gm9795 in NASH were explored by knocking down or over-expressing its expression.

Results

A total of 381 lncRNAs were found to be not only highly expressed in NAFLD, but also is going to go even higher in NASH. A novel LncRNA-gm9795 was significantly highly expressed in liver tissues of NASH animal models and NASH cell models. By staining with Nile red, we found that gm9795 did not affect the fat accumulation of NASH. However, gm9795 in NASH cell models significantly promoted the expression of TNF \(\alpha {}\), IL-6, IL-1\(\beta {}\), the important inflammatory mediators in NASH. At the same time, we found that gm9795 upregulated the key molecules in endoplasmic reticulum stress (ERS), while NF-\(\kappa {}\)B/JNK pathways were also activated. When ERS activator Thapsigargin (TG) was introduced in cells with Ggm9757 si-RNA, NF-\(\kappa {}\)B and JNK pathways were activated. Conversely, ERS inhibitor Tauroursodeoxycholic acid (TUDCA) inhibited NF-kB and JNK pathways in cells with gm9795 overexpression plasmid.

Conclusion

LncRNA-gm9795 promotes inflammatory response in NASH through NF-kB and JNK pathways by ERS, which might provide theoretical basis for revealing the pathogenesis of NASH and discovering new therapeutic targets
Literature
1.
go back to reference Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.CrossRef Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.CrossRef
2.
go back to reference Wong S, Chan W. Epidemiology of non-alcoholic fatty liver disease in Asia. Indian J Gastroenterol. 2020;39(1):1–8.CrossRef Wong S, Chan W. Epidemiology of non-alcoholic fatty liver disease in Asia. Indian J Gastroenterol. 2020;39(1):1–8.CrossRef
3.
go back to reference Wang L, et al. Endoplasmic reticulum stress related molecular mechanisms in nonalcoholic fatty liver disease (NAFLD). Curr Drug Targets. 2018;19(9):1087–94.CrossRef Wang L, et al. Endoplasmic reticulum stress related molecular mechanisms in nonalcoholic fatty liver disease (NAFLD). Curr Drug Targets. 2018;19(9):1087–94.CrossRef
4.
go back to reference Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76(1):99–128.CrossRef Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76(1):99–128.CrossRef
5.
go back to reference Fang YL, et al. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from “two hit theory’’ to “multiple hit model’’. World J Gastroenterol. 2018;24(27):2974–83.CrossRef Fang YL, et al. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from “two hit theory’’ to “multiple hit model’’. World J Gastroenterol. 2018;24(27):2974–83.CrossRef
6.
go back to reference Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–48.CrossRef Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–48.CrossRef
7.
go back to reference Ashraf NU, Sheikh TA. Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. Free Radical Res. 2015;49(12):1405–18.CrossRef Ashraf NU, Sheikh TA. Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. Free Radical Res. 2015;49(12):1405–18.CrossRef
8.
go back to reference Chi Y, et al. Long noncoding RNA lncARSR promotes nonalcoholic fatty liver disease and hepatocellular carcinoma by promoting YAP1 and activating the IRS2/AKT pathway. J Transl Med. 2020;18(1):126.CrossRef Chi Y, et al. Long noncoding RNA lncARSR promotes nonalcoholic fatty liver disease and hepatocellular carcinoma by promoting YAP1 and activating the IRS2/AKT pathway. J Transl Med. 2020;18(1):126.CrossRef
9.
go back to reference Chen Y, et al. Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl-Sirt1 pathway. FASEB J. 2019;33(10):11411–9.CrossRef Chen Y, et al. Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl-Sirt1 pathway. FASEB J. 2019;33(10):11411–9.CrossRef
10.
go back to reference Takahashi K, et al. Long noncoding RNA in liver diseases. Hepatology. 2014;60(2):744–53.CrossRef Takahashi K, et al. Long noncoding RNA in liver diseases. Hepatology. 2014;60(2):744–53.CrossRef
11.
go back to reference Wang H, et al. Long non-coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes. J Cell Mol Med. 2020;24(2):1399–412.CrossRef Wang H, et al. Long non-coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes. J Cell Mol Med. 2020;24(2):1399–412.CrossRef
12.
go back to reference Zhao Y, et al. Long non-coding RNA in liver metabolism and disease: current status. Liver Res. 2017;1(3):163–7.CrossRef Zhao Y, et al. Long non-coding RNA in liver metabolism and disease: current status. Liver Res. 2017;1(3):163–7.CrossRef
13.
go back to reference Jacq C, Miller JR, Brownlee GG. A pseudogene structure in 5S DNA of Xenopus laevis. Cell. 1977;12(1):109–20.CrossRef Jacq C, Miller JR, Brownlee GG. A pseudogene structure in 5S DNA of Xenopus laevis. Cell. 1977;12(1):109–20.CrossRef
14.
go back to reference Lou W, Ding B, Fu P. Pseudogene-derived lncRNAs and their miRNA sponging mechanism in human cancer. Front Cell Dev Biol. 2020;8:85.CrossRef Lou W, Ding B, Fu P. Pseudogene-derived lncRNAs and their miRNA sponging mechanism in human cancer. Front Cell Dev Biol. 2020;8:85.CrossRef
15.
go back to reference Xiao-Jie L, et al. Pseudogene in cancer: real functions and promising signature. J Med Gene. 2014;52(1):17–24.CrossRef Xiao-Jie L, et al. Pseudogene in cancer: real functions and promising signature. J Med Gene. 2014;52(1):17–24.CrossRef
16.
go back to reference Chen X, et al. LncRNA-AK012226 is involved in fat accumulation in db/db mice fatty liver and non-alcoholic fatty liver disease cell model. Front Pharmacol. 2018;9:888.CrossRef Chen X, et al. LncRNA-AK012226 is involved in fat accumulation in db/db mice fatty liver and non-alcoholic fatty liver disease cell model. Front Pharmacol. 2018;9:888.CrossRef
17.
go back to reference Mai W, et al. viaBerberine inhibits nod-like receptor family pyrin domain containing 3 inflammasome activation and pyroptosis in nonalcoholic steatohepatitis the ROS/TXNIP axis. Front Pharmacol. 2020;11:185.CrossRef Mai W, et al. viaBerberine inhibits nod-like receptor family pyrin domain containing 3 inflammasome activation and pyroptosis in nonalcoholic steatohepatitis the ROS/TXNIP axis. Front Pharmacol. 2020;11:185.CrossRef
18.
go back to reference Greter M, Lelios I, Croxford AL. Microglia versus myeloid cell nomenclature during brain inflammation. Front Immunol. 2015;6:249.CrossRef Greter M, Lelios I, Croxford AL. Microglia versus myeloid cell nomenclature during brain inflammation. Front Immunol. 2015;6:249.CrossRef
19.
go back to reference Barth DA, et al. Long-noncoding RNA (lncRNA) in the regulation of hypoxia-inducible factor (HIF) in cancer. Noncod RNA. 2020;6(3):27. Barth DA, et al. Long-noncoding RNA (lncRNA) in the regulation of hypoxia-inducible factor (HIF) in cancer. Noncod RNA. 2020;6(3):27.
20.
go back to reference Zottel A, et al. Coding of glioblastoma progression and therapy resistance through long noncoding RNAs. Cancers. 2020;12(7):1842.CrossRef Zottel A, et al. Coding of glioblastoma progression and therapy resistance through long noncoding RNAs. Cancers. 2020;12(7):1842.CrossRef
21.
go back to reference Huang P, et al. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6. Metabolism. 2019;94:1–8.CrossRef Huang P, et al. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6. Metabolism. 2019;94:1–8.CrossRef
22.
go back to reference Makhmudi A, et al. The effect of APTR, Fn14 and CD133 expressions on liver fibrosis in biliary atresia patients. Pediatric Surger Int. 2020;36(1):75–9.CrossRef Makhmudi A, et al. The effect of APTR, Fn14 and CD133 expressions on liver fibrosis in biliary atresia patients. Pediatric Surger Int. 2020;36(1):75–9.CrossRef
23.
go back to reference Leti F, et al. Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells. Translat Res. 2017;190:25-39.e21.CrossRef Leti F, et al. Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells. Translat Res. 2017;190:25-39.e21.CrossRef
24.
go back to reference Gariani K, Jornayvaz FR. NASH: a less known but severe complication of diabetes. Rev Med Suisse. 2020;16(697):1197–9.PubMed Gariani K, Jornayvaz FR. NASH: a less known but severe complication of diabetes. Rev Med Suisse. 2020;16(697):1197–9.PubMed
25.
go back to reference Lefere S, Devisscher L, Geerts A. Angiogenesis in the progression of non-alcoholic fatty liver disease. Acta Gastroenterol Belg. 2020;83(2):301–7.PubMed Lefere S, Devisscher L, Geerts A. Angiogenesis in the progression of non-alcoholic fatty liver disease. Acta Gastroenterol Belg. 2020;83(2):301–7.PubMed
26.
go back to reference Lebeaupin C, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2018;69(4):927–47.CrossRef Lebeaupin C, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2018;69(4):927–47.CrossRef
27.
go back to reference Zhou X, et al. Glucose regulated protein 78 is potentially an important player in the development of nonalcoholic steatohepatitis. Gene. 2017;637:138–44.CrossRef Zhou X, et al. Glucose regulated protein 78 is potentially an important player in the development of nonalcoholic steatohepatitis. Gene. 2017;637:138–44.CrossRef
28.
go back to reference Vallee D, et al. Endoplasmic reticulum stress response and pathogenesis of non-alcoholic steatohepatitis. Med Sci. 2020;36(2):119–29. Vallee D, et al. Endoplasmic reticulum stress response and pathogenesis of non-alcoholic steatohepatitis. Med Sci. 2020;36(2):119–29.
29.
go back to reference Jiang H, et al. Strontium alleviates endoplasmic reticulum stress in a nonalcoholic fatty liver disease model. J Med Food. 2018;21:1228–37.CrossRef Jiang H, et al. Strontium alleviates endoplasmic reticulum stress in a nonalcoholic fatty liver disease model. J Med Food. 2018;21:1228–37.CrossRef
Metadata
Title
LncRNA-Gm9795 promotes inflammation in non-alcoholic steatohepatitis via NF-B/JNK pathway by endoplasmic reticulum stress
Authors
Liangying Ye
Dan Zhao
Yangzhi Xu
Jiaen Lin
Jiahui Xu
Kunyuan Wang
Zhanhui Ye
Yufeng Luo
Shiming Liu
Hui Yang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-02769-7

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.